选择性D-1多巴胺受体激动剂在运动亢进性锥体外系疾病中的作用
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.
作者信息
Braun A, Mouradian M M, Mohr E, Fabbrini G, Chase T N
机构信息
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
出版信息
J Neurol Neurosurg Psychiatry. 1989 May;52(5):631-5. doi: 10.1136/jnnp.52.5.631.
Abstract
The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.
摘要
采用双盲安慰剂对照设计，评估了选择性D-1多巴胺受体激动剂SKF 39393对亨廷顿舞蹈症、抽动秽语综合征、迟发性运动障碍和扭转性肌张力障碍患者的运动和认知影响。在每日剂量范围为3.2至32mg/kg且治疗间隔为1至7周的情况下，未发现一致的变化。D-1受体介导的机制对运动过度性锥体外系疾病病理生理学的作用仍不确定。
相似文献
1
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders.选择性D-1多巴胺受体激动剂在运动亢进性锥体外系疾病中的作用
J Neurol Neurosurg Psychiatry. 1989 May;52(5):631-5. doi: 10.1136/jnnp.52.5.631.
2
Progabide in the treatment of hyperkinetic extrapyramidal movement disorders.丙戊茶碱治疗运动亢进型锥体外系运动障碍
Acta Neurol Scand. 1985 Sep;72(3):341-3. doi: 10.1111/j.1600-0404.1985.tb00881.x.
3
The effect of dopamine antagonists in spontaneous and tardive dyskinesia.多巴胺拮抗剂在自发性和迟发性运动障碍中的作用。
Psychopharmacology Suppl. 1985;2:118-21. doi: 10.1007/978-3-642-70140-5_15.
4
Dopamine D-1 receptor agonist stimulation of prolactin secretion in man.多巴胺D-1受体激动剂对人催乳素分泌的刺激作用。
J Neural Transm. 1988;71(3):159-63. doi: 10.1007/BF01245709.
5
Selective D-1 dopamine receptor agonist treatment of Parkinson's disease.帕金森病的选择性D-1多巴胺受体激动剂治疗
J Neural Transm. 1987;68(1-2):41-50. doi: 10.1007/BF01244638.
6
The trial use of clozapine for abnormal involuntary movement disorders.氯氮平用于异常不自主运动障碍的试验性应用。
Am J Psychiatry. 1979 Mar;136(3):317-20. doi: 10.1176/ajp.136.3.317.
7
Talipexole and adult Gilles de la Tourette's syndrome: double-blind, placebo-controlled clinical trial.他立哌唑与成人抽动秽语综合征：双盲、安慰剂对照临床试验。
Mov Disord. 1994 May;9(3):315-7. doi: 10.1002/mds.870090306.
8
Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.多巴胺D1受体参与SKF 81297对松鼠猴的辨别刺激效应。
J Pharmacol Exp Ther. 1993 Nov;267(2):765-75.
9
Are D1 dopamine receptor agonists potential antidepressants?D1多巴胺受体激动剂是潜在的抗抑郁药吗？
Pharmacol Res Commun. 1988 Dec;20(12):1121-2. doi: 10.1016/s0031-6989(88)80756-2.
10
A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.舒必利治疗亨廷顿舞蹈病和迟发性运动障碍的双盲试验。
J Neurol Neurosurg Psychiatry. 1984 Aug;47(8):844-7. doi: 10.1136/jnnp.47.8.844.
引用本文的文献
1
Non-antipsychotic catecholaminergic drugs for antipsychotic-induced tardive dyskinesia.用于抗精神病药物所致迟发性运动障碍的非抗精神病类儿茶酚胺能药物。
Cochrane Database Syst Rev. 2018 Jan 18;1(1):CD000458. doi: 10.1002/14651858.CD000458.pub3.
2
Direct inhibition of the N-methyl-D-aspartate receptor channel by dopamine and (+)-SKF38393.多巴胺和(+)-SKF38393对N-甲基-D-天冬氨酸受体通道的直接抑制作用
Br J Pharmacol. 1999 Apr;126(8):1847-55. doi: 10.1038/sj.bjp.0702479.
本文引用的文献
1
Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease.对既往未经治疗的帕金森病患者进行溴隐亭持续治疗。
J Neurol Neurosurg Psychiatry. 1981 Nov;44(11):1020-3. doi: 10.1136/jnnp.44.11.1020.
2
Resolution and absolute configuration of an ergoline-related dopamine agonist, trans-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H(or 2H)-pyrazolo[3,4-g]quinoline.一种麦角灵相关多巴胺激动剂反式-4,4a,5,6,7,8,8a,9-八氢-5-丙基-1H(或2H)-吡唑并[3,4-g]喹啉的拆分及绝对构型
J Med Chem. 1983 Aug;26(8):1112-6. doi: 10.1021/jm00362a005.
3
Abnormal involuntary movements: a study of dopaminergic receptor interaction.异常不自主运动：多巴胺能受体相互作用的研究
Adv Neurol. 1983;37:305-12.
4
Behavioral correlations of dopamine receptor activation.多巴胺受体激活的行为相关性。
Neurology. 1983 Nov;33(11):1489-92. doi: 10.1212/wnl.33.11.1489.
5
Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.D1激动剂R-SK & F 38393可立体特异性地促进多巴胺能行为，并被D1拮抗剂SCH 23390选择性阻断。
Psychopharmacology (Berl). 1984;82(4):409-10. doi: 10.1007/BF00427697.
6
SCH-23390: a selective D1 dopamine antagonist with potent D2 behavioral actions.
Eur J Pharmacol. 1984 May 18;101(1-2):159-60. doi: 10.1016/0014-2999(84)90044-x.
7
The classification of dopamine receptors: relationship to radioligand binding.多巴胺受体的分类：与放射性配体结合的关系。
Annu Rev Neurosci. 1983;6:43-71. doi: 10.1146/annurev.ne.06.030183.000355.
8
The Leyton obsessional inventory.莱顿强迫观念量表
Psychol Med. 1970 Nov;1(1):48-64. doi: 10.1017/s0033291700040010.
9
10
Obligatory D-1/D-2 receptor interaction in the generation of dopamine agonist related behaviors.多巴胺激动剂相关行为产生中D-1/D-2受体的强制性相互作用。
Eur J Pharmacol. 1986 Nov 19;131(2-3):301-6. doi: 10.1016/0014-2999(86)90588-1.
Zotero 插件